CRNX240517P55000
- 4.55
- 0.000.00%
Crinetics Newsroom
Cantor Fitzgerald Maintains Crinetics(CRNX.US) With Buy Rating, Raises Target Price to $75
Cantor Fitzgerald analyst Joshua Schimmer maintains $Crinetics(CRNX.US)$ with a buy rating, and adjusts the target price from $65 to $75.According to TipRanks data, the analyst has a success rate of 5
Baird Maintains Crinetics(CRNX.US) With Buy Rating, Raises Target Price to $62
Baird analyst Brian Skorney maintains $Crinetics(CRNX.US)$ with a buy rating, and adjusts the target price from $52 to $62.According to TipRanks data, the analyst has a success rate of 41.7% and a tot
Analysts Offer Insights on Healthcare Companies: Crinetics Pharmaceuticals (CRNX) and BioMarin Pharmaceutical (BMRN)
A Quick Look at Today's Ratings for Crinetics(CRNX.US), With a Forecast Between $60 to $80
On May 23, major Wall Street analysts update their ratings for $Crinetics(CRNX.US)$, with price targets ranging from $60 to $80.Morgan Stanley analyst Jeffrey Hung maintains with a buy rating, and adj
Express News | HC Wainwright & Co. Reiterates Buy on Crinetics Pharmaceuticals, Maintains $60 Price Target
Express News | Crinetics Pharmaceuticals Inc : Baird Raises Target Price to $62 From $52
Analysts Are Bullish on These Healthcare Stocks: Crinetics Pharmaceuticals (CRNX), Lipella Pharmaceuticals, Inc. (LIPO)
Buy Rating Affirmed for Crinetics Pharmaceuticals Amid Promising Atumelnant Data for CAH
Crinetics Pharma Gains After Early Release of Study Data
Market-Moving News for May 22nd
CRNX: 11% | Crinetics Pharmaceuticals shares are trading higher after the company announced the early release of ENDO 2024 late-breaking abstracts.BZFD: 69% | BuzzFeed shares are trading higher after
Express News | Crinetics Pharmaceuticals Shares Are Trading Higher After the Company Announced the Early Release of ENDO 2024 Late-breaking Abstracts
Crinetics Pharmaceuticals Announces Early Release of ENDO 2024 Late-Breaking Abstracts
SAN DIEGO, May 22, 2024 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) a clinical stage pharmaceutical company focused on the discovery, development and commercialization of novel therapeutics for
Crinetics(CRNX.US) Officer Sells US$148.29K in Common Stock
$Crinetics(CRNX.US)$ Officer Betz Stephen F. sold 3,000 shares of common stock on May 10, 2024 at an average price of $49.43 for a total value of $148.29K.Source: Announcement What is statement of cha
18 Analysts Have This To Say About Crinetics Pharmaceuticals
In the last three months, 18 analysts have published ratings on Crinetics Pharmaceuticals (NASDAQ:CRNX), offering a diverse range of perspectives from bullish to bearish.The table below provides a con
Express News | Cantor Fitzgerald Reiterates Overweight on Crinetics Pharmaceuticals, Maintains $65 Price Target
Analysts Offer Insights on Healthcare Companies: Crinetics Pharmaceuticals (CRNX), Wave Life Sciences (WVE) and Intellia Therapeutics (NTLA)
Oppenheimer Reaffirms Their Buy Rating on Crinetics Pharmaceuticals (CRNX)
Investors in Crinetics Pharmaceuticals (NASDAQ:CRNX) Have Seen Solid Returns of 196% Over the Past Three Years
Crinetics(CRNX.US) Officer Sells US$5.31 Million in Common Stock
$Crinetics(CRNX.US)$ Officer Struthers Richard Scott sold 107.45K shares of common stock on May 8, 2024 at an average price of $49.4 for a total value of $5.31 million.Source: Announcement What is sta
Express News | Crinetics Pharmaceuticals Announces May 2024 Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)